PROVETOP

Biotinylated Human KIR2DL1 Protein

Catalog No: KIR2DL1-HB001

Species
Human
Expression System
HEK293
Tag
His, Avi

Product overview

Recombinant Biotinylated Human KIR2DL1 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues His22-Arg242 (UniProt accession: P43626).

Product Details

Molecular Aliases
CD158Ankat1; CD158A; cl-42; KIR2DL1; NKAT; NKAT-1; p58.1; KIR-K64; KIR221; KIR2DL1/KIR2DS5;cl42; NKAT1
Protein Length
His22-Arg242
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 27.1 kDa. Due to glycosylation, the protein migrates to 48-60 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
KIR2DL1-HB001 Bis-Tris-PAGE-white result

Biotinylated Human KIR2DL1 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

SEC-HPLC
KIR2DL1-HB001 SEC-HPLC result

The purity of Biotinylated Human KIR2DL1 is greater than 95% as determined by SEC-HPLC.

Background

KIR2DL1 (2DL1, formerly NKAT1, designated CD158a) is a 348 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig-like receptor (KIR) family.KIR2DL1 is a receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis.

References

  1. Yoon S R, Kim T D, Choi I. Understanding of molecular mechanisms in natural killer cell therapy[J]. Experimental & Molecular Medicine, 2015, 47(2):e141.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support